Merck KGaA CFO on Covid-19 Vaccine, Demand, Semiconductors

The transcript discusses the changing expectations due to the COVID-19 pandemic, with a focus on the visibility into 2020 and 2021. It covers the potential normalization of demand by the end of the year, with specific impacts on various business sectors such as pharmaceuticals, semiconductors, and life sciences. The discussion also touches on the future demand in life sciences and the challenges in vaccine development, emphasizing the importance of risk management and government investment.

What challenges does the speaker foresee for the fertility business due to the pandemic?

How does the speaker assess the current demand situation in life sciences?

What is the speaker's view on the timeline for vaccine development and its distribution?